Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage drug manufacturer producing and commercializing potential top in class oncology and CNS therapeutics, introduced that it has submitted a Phase II protocol for clinical study of Archexin® as a remedy of ovarian cancer towards the U.S. Food and Drug Administration (FDA).The Phase II study can detrmine the protection and performance of Archexin especially when using in combination with both carboplatin and paclitaxel to be a second-line therapy in things which are platinum-sensitive following their personal first relapse. The research will be performed at numerous centers in the United States, and subjects will probably be randomized to obtain either carboplatin/paclitaxel or carboplatin/paclitaxel/Archexin. Various actions of clinical benefit will probably be evaluated.
Ovarian cancer would be the fifth most typical cancer among ladies, and it also causes more deaths compared to any other type of female reproductive cancer.
"Treatment solutions are limited for affected individuals that are stricken along with ovarian cancer, thus we look forward to investigating Archexin as a possible mixture treatment for the disease." said Rick Soni, President of Rexahn. "To this point, Archexin has proved potentially promising safety profile, and has been granted orphan drug designation in ovarian cancer and a number of other solid tumors from the FDA. We would like to report preliminary Phase II results away from pancreatic cancer trial along with Archexin later this season."
No comments:
Post a Comment